Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.

[1]  J. Broom,et al.  Facilitating treatment of HCV in primary care in regional Australia: closing the access gap , 2018, Frontline Gastroenterology.

[2]  B. Cowie,et al.  Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001–2012: a multi‐level modelling analysis , 2017, Australian and New Zealand journal of public health.

[3]  M. Alavi,et al.  Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment , 2017, Journal of gastroenterology and hepatology.

[4]  G. Dore,et al.  Hepatitis C treatment as prevention: evidence, feasibility, and challenges. , 2016, The lancet. Gastroenterology & hepatology.

[5]  M. Alavi,et al.  Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. , 2016, Addiction.

[6]  C. Beyrer,et al.  HIV treatment cascade in MSM, people who inject drugs, and sex workers , 2015, Current opinion in HIV and AIDS.

[7]  G. Dore,et al.  Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. , 2015, The International journal on drug policy.

[8]  G. Dore,et al.  The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention , 2015, Current opinion in HIV and AIDS.

[9]  M. Kretzschmar,et al.  Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? , 2015, Addiction.

[10]  Julio S. G. Montaner,et al.  The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. , 2014, Addiction.

[11]  J. Hahn,et al.  Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. , 2014, JAMA internal medicine.

[12]  G. Dore,et al.  Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS‐c study , 2014, The Medical journal of Australia.

[13]  M. Alavi,et al.  Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[14]  J. Lazarus,et al.  Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.

[15]  C. Umscheid,et al.  The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis , 2014, PloS one.

[16]  M. Weinstein,et al.  The Hepatitis C Cascade of Care: Identifying Priorities to Improve Clinical Outcomes , 2014, PloS one.

[17]  V. Soriano,et al.  Towards hepatitis C eradication from the HIV-infected population. , 2014, Antiviral research.

[18]  H. Wand,et al.  Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.

[19]  G. Lauer,et al.  The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection , 2014, Hepatology.

[20]  R. Schinazi,et al.  Treatment as prevention and cure towards global eradication of hepatitis C virus. , 2013, Trends in microbiology.

[21]  G. Dore,et al.  Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. De Angelis,et al.  Multiple parameter evidence synthesis--a potential solution for when information on drug use and harm is in conflict. , 2013, Addiction.

[23]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[24]  M. Alavi,et al.  Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Kaldor,et al.  Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. , 2013, American journal of public health.

[26]  A. Lloyd,et al.  Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  G. Dore,et al.  Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. , 2013, The Journal of infectious diseases.

[28]  A. White,et al.  Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. , 2012, Journal of substance abuse treatment.

[29]  L. Maher,et al.  HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment , 2012, Current opinion in HIV and AIDS.

[30]  G. Dore.  The changing therapeutic landscape for hepatitis C , 2012, The Medical journal of Australia.

[31]  H. Wand,et al.  Individual-level syringe coverage among Needle and Syringe Program attendees in Australia. , 2012, Drug and alcohol dependence.

[32]  L. Maher.  Tackling hepatitis C in Australia: the third national strategy. , 2012, The Lancet. Infectious diseases.

[33]  C. Mcgowan,et al.  Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[34]  C. Treloar,et al.  Staying Safe From Hepatitis C , 2012, Qualitative health research.

[35]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[36]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[37]  Carlos Del Rio,et al.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  M. Volk.  Antiviral therapy for hepatitis C: why are so few patients being treated? , 2010, The Journal of antimicrobial chemotherapy.

[39]  P. Haber,et al.  Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C , 2010, The Medical journal of Australia.

[40]  J. Kaldor,et al.  Representativeness of Injecting Drug Users Who Participate in HIV Surveillance: Results From Australia's Needle and Syringe Program Survey , 2008, Journal of acquired immune deficiency syndromes.

[41]  B. Conway,et al.  Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. , 2008, Drug and alcohol dependence.

[42]  G. Dore,et al.  Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  J. Kaldor,et al.  HIV prevalence and risk behaviour in needle exchange attenders: a national study , 1997 .